Fluorometric screening for metabolism-based drug--drug interactions

Area of Science:

• Pharmacology
• Drug Metabolism
• Biochemistry

Background:

• Cytochrome P-450 (CYP) enzyme inhibition is a primary driver of drug-drug interactions.
• Established in vitro methods for quantifying CYP inhibition often rely on HPLC analysis, which can be time-consuming and costly.
• High-throughput screening (HTS) is essential in modern drug discovery for efficient compound evaluation.

Purpose of the Study:

• To describe the implementation of a high-throughput, fluorometric assay for measuring CYP inhibition.
• To establish a quantitative, rapid, and reproducible methodology for assessing CYP enzyme activity in a drug discovery setting.
• To present an alternative to traditional HPLC-based methods for CYP inhibition studies.

Main Methods:

• Utilized multiwell plate-based, direct, fluorometric assays for assessing the activity of major drug-metabolizing enzymes.
• Established assay parameters for using specific substrates to measure CYP inhibition.
• Validated the methodology for compatibility with standard high-throughput screening instrumentation.

Main Results:

• The fluorometric assay provides quantitative, rapid, and reproducible measurements of CYP inhibition.
• The methodology eliminates the need for HPLC separation, increasing throughput and reducing costs.
• The approach is suitable for integration into drug discovery support programs.

Conclusions:

• Direct fluorometric assays represent a valuable, high-throughput alternative for quantitative assessment of CYP inhibition.
• This methodology facilitates efficient screening of drug candidates for potential metabolism-based interactions.
• Implementing this assay streamlines the drug discovery process by providing faster, more cost-effective data.